Arrowhead Pharmaceuticals Announces Long-Term Efficacy Data for Plozasiran
Arrowhead Pharmaceuticals announced long-term efficacy and safety data from a two-year long open-label extension, OLE, study of investigational plozasiran supporting its potential as therapeutic solution for a diverse spectrum of patients with hypertriglyceridemia, HTG. In both studies, the majority of patients achieved TG levels below thresholds for acute pancreatitis risk or below normal thresholds. 96% of sHTG patients achieved TGs below 500 mg/dL and 63% achieved TGs below 150 mg/dL, a threshold associated with increased risk of ASCVD. 93% of HTG patients achieved TGs below 150 mg/dL. These findings support the potential of plozasiran as a promising approach for managing patients with moderate to severe HTG phenotypes who are at risk of AP and potentially other cardiometabolic comorbidities. Plozasiran demonstrated a consistent long-term safety and tolerability profile across both sHTG and HTG patient populations, with stable glycemic parameters, no clinically meaningful differences in routine clinical laboratory measurements, and no new safety signals.
